Professor John Greenman J.Greenman@hull.ac.uk
Professor of Tumour Immunology
Professor John Greenman J.Greenman@hull.ac.uk
Professor of Tumour Immunology
Background: Currently, calcitonin, thyroglobulin and thyroid stimulating hormone receptor antibodies (TSH-R-Ab) can help monitor thyroid cancer post-operatively, however, these cannot distinguish between benign and malignant neoplasms, or between different severity of disease pre-operatively (Xiao et al., 2020; Macvanin et al. 2023). The identification of new biomarkers would not only help in cancer diagnosis, they would also help monitor the progress of disease in patients with microcarcinomas, where diagnosis often leads to over treatment (Zaridze et al., 2021; Sugitani et al., 2021). Similarly, TSH-R-Ab are used to monitor Graves’ disease, but further biomarkers which might identify patients likely to develop severe eye disease would help in the management of the disease (Zhang et al., 2018).
Aim: To determine differences in expression of a focussed panel of miRNA in the serum of patients with benign thyroid disease and thyroid carcinoma compared to healthy individuals.
Preliminary work: Thyroid tissue (benign [non-Graves’], Graves’ and carcinoma), have been incubated in a tissue-on-chip device allowing the collection of tissue-derived small extracellular vesicles (sEV). The microRNA (miR) from these sEV has been extracted and sequenced. Significant up-regulation of miR-375-3p, miR-7-5p, miR-382-5p, and miR-127-3p was observed in sEV from Graves’ tissue compared to those from other benign tissue. Similarly, miR-375-3p and miR-7-5p were also significantly up-regulated in sEV from Graves’ tissue compared to sEV from cancer tissue. No difference was observed between cancer and benign sEV. qRT-PCR validation similarly found elevated levels of miR-375-3p and miR-382-5p in Graves’ tissue sEV compared to benign tissue sEV but this difference was not significant. In contrast to the sequencing data, miR-375-3p, miR-382-5p, and miR-127-3p were all up-regulated in cancer sEV compared to benign sEV (Haigh et al., 2023). The plan for the current study is to utilise this preliminary data to determine whether differences in expression of these miRs and others which tended towards significance, can also be detected in patient’s serum compared to those from healthy individuals. The serum has already been collected from 26 patients and the remaining samples will be collected over the first 6 months of the project, based on previous recruitment.
Objective: To use qRT-PCR to measure the levels of previously identified miRNA of interest in sEV isolated from serum of healthy individuals (n=15), patients with benign thyroid disease, including Graves’ (n=15) and patients with thyroid carcinoma (n=15).
sEV will be isolated by ultracentrifugation from all serum samples (Thery et al., 2016) and RNA extracted using the QIAGEN miRNeasy microkit. qRT-PCR will be used to quantify the levels of a panel of up to 10 miRNA (including miR-375-3p, miR-7-5p, miR-382-5p, and miR-127-3p) that were found to be of interest using the previous sequencing data. Comparison between the different thyroid pathologies will be achieved using the GeneGlobe analysis tool following normalisation against stable miR using geNorm (Qiagen). This will identify potential miRNA biomarkers which will then be evaluated in a larger, multi-centre study.
Status | Project Live |
---|---|
Funder(s) | British Association of Endocrine & Thyroid Surgeons |
Value | £5,000.00 |
Project Dates | Jul 1, 2024 - Jun 30, 2025 |
This project contributes to the following UN Sustainable Development Goals |
|
Blood test for clinical therapy guidance of non-small cell lung cancer patients Jan 1, 2017 - Oct 31, 2022
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patie...
Read More about Blood test for clinical therapy guidance of non-small cell lung cancer patients.
The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture. Jun 1, 2017 - May 31, 2018
Graves’ disease (GD) affects approximately 2% of adult women. Current treatments for GD include anti-thyroid drugs, radioiodine therapy and surgery, of which none tackle the underlying pathogenic process. Immunosuppressive agents are therefore of gro...
Read More about The effect of corticosteroids on the release of immune modulating factors from Graves’ disease tissue maintained using microfluidic culture..
Development of a multipurpose small animal phantom for pre-clinical radiotherapy studies Apr 1, 2016 - Mar 31, 2019
The project aims to both reduce the total number of animals used for preclinical radiotherapy experiments whilst concurrently increasing the accuracy of such investigations in order to maximise their clinical impact. This will be achieved through the...
Read More about Development of a multipurpose small animal phantom for pre-clinical radiotherapy studies.
The Hull-Norwich Gut-Brian Study May 31, 2016 - Jun 30, 2018
Objective To obtain mechanistic insights into how resident commensal gut bacteria (the microbiota) influences host physiology and in particular brain function and host behaviour. The focus is on identifying the pathways and molecules originating from...
Read More about The Hull-Norwich Gut-Brian Study.
Lab on a Chip NC3Rs Engagement Award Aug 15, 2016 - Aug 14, 2017
This project will deliver a programme of public engagement with innovative hands-on activities in the area of tissue/organ-on-a-chip which are emerging as life-like models to reduce and replace animal testing to school children and the general public...
Read More about Lab on a Chip NC3Rs Engagement Award.
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search